Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy

Full text
Author(s):
de Carvalho, Samara Camacari [1] ; Matsumura, Cintia Yuri [1] ; Neto, Humberto Santo [1] ; Marques, Maria Julia [1]
Total Authors: 4
Affiliation:
[1] Univ Campinas UNICAMP, Inst Biol, Dept Struct & Funct Biol, BR-13083865 Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: CYTOKINE; v. 102, p. 55-61, FEB 2018.
Web of Science Citations: 2
Abstract

Duchenne muscular dystrophy (DMD) is a progressive and fatal disease, characterized by the absence of dystrophin, muscle degeneration and cardiorespiratory failure. Creatine kinase is the classic marker to screen for DMD. However, other markers are needed to follow disease progression and to evaluate the response to therapy over longer periods. In the present study, we aim to identify interleukins in the plasma of the mdx mice model of DMD that could serve as biomarkers to monitor dystrophy progression, at distinct stages of the disease (1, 3 and 8 months of age). We used deflazacort and omega-3 therapies to validate the biomarkers studied. Plasma levels of TNF-alpha and TGF-beta were increased in mdx mice in relation to control, at all times studied. Differences in IFN-gamma and IL-10 contents, comparing mdx x CTRL, were detected only at the early stage (1 month). IL-6 decreased at 3 and 8 months and IL-13 increased at 8 months in the mdx compared to control. Deflazacort and omega-3 reduced the plasma levels of the pro-inflammatory (TNF-alpha, INF-gamma, IL-6) and pro-fibrotic (IL-13 and TGF-beta) interleukins and increased the plasma levels of IL-10. It is suggested that TNF-alpha and TGF-beta in plasma would be the best markers to follow disease progression. IL-6, INF-gamma and IL-10 would be suitable markers to the earlier stages of dystrophy and IL-13 a suitable marker to the later stages of dystrophy. (AU)

FAPESP's process: 14/04782-6 - Pre-clinical studies in the mdx mouse: metabolomics, biomarkers and omega-3 therapy
Grantee:Maria Julia Marques
Support type: Regular Research Grants
FAPESP's process: 13/00312-2 - Biomarkers of Duchenne muscular dystrophy: metabolomic and immunoassay study in patients and in mdx mice
Grantee:Cintia Yuri Matsumura
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 12/15492-3 - Pharmacological therapy of the dystrophinopathies: fibrosis and muscular regeneration in mdx mice treated with omega-3
Grantee:Samara Camaçarí de Carvalho
Support type: Scholarships in Brazil - Doctorate